Nationwide survey of hepatitis D virus prevalence in Thailand
Prevalence, Risk Factor and Clinical Significance of Hepatitis D Virus Infection Among Targeted High Risk Population in Thailand: Nationwide Survey 2022-2024
The HIV Netherlands Australia Thailand Research Collaboration · NCT05350865
This study is trying to find out how common hepatitis D is among people in Thailand who inject drugs and are also living with HIV or hepatitis B.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3152 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The HIV Netherlands Australia Thailand Research Collaboration (other) |
| Locations | 4 sites (Bangkok, Bangkok and 3 other locations) |
| Trial ID | NCT05350865 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prevalence and predictors of hepatitis D virus (HDV) among people who inject drugs (PWID) in Thailand, particularly those co-infected with HIV and HBV. The study will gather data on the burden of HDV in this population, which is currently under-researched. Collaborating with various Thai health organizations, the findings will help inform guidelines for HDV screening and treatment, addressing a significant unmet need in public health. The study will include participants aged 18 and older who are chronically infected with HBV.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 18 and older who are chronically infected with HBV.
Not a fit: Patients who do not have chronic HBV infection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved screening and treatment strategies for HDV among vulnerable populations in Thailand.
How similar studies have performed: While there is limited data on HDV in Thailand, similar studies in other regions have successfully highlighted the importance of HDV screening in HBV patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female, aged 18 years and older 2. Chronically-infected with HBV, as defined by: Positive Hepatitis B surface antigen HBsAg) or HBV DNA result with a subsequent positive HBsAg or HBV DNA result at least 6 months after first positive result 3. Provide signed and dated informed consent form. Exclusion Criteria: Non chronic HBV
Where this trial is running
Bangkok, Bangkok and 3 other locations
- HIV-NAT, Thai Red Cross - AIDS Research Centre — Bangkok, Bangkok, Thailand (RECRUITING)
- King memorial Chulalongkorn hospital — Bangkok, Bangkok, Thailand (RECRUITING)
- Siriraj Hospital, Mahidol University — Bangkok, Bangkok, Thailand (RECRUITING)
- Taksin Hospital — Bangkok, Bangkok, Thailand (RECRUITING)
Study contacts
- Principal investigator: Anchalee Avihingsanon, MD, PhD — Thai Red Cross AIDS Research Centre
- Study coordinator: Chatsuda Auchieng
- Email: chatsuda.a@hivnat.org
- Phone: 6626523040
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: HDV, HBV, cirrhosis, Thailand